AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9089857 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine and self-administration of 0.6 mg every 30 minutes
Number of subjects: 42
Study 9089857 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of 3.75 mg of plain bupivacaine on request
Number of subjects: 42
Study 9089857 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with a constant subarachnoid infusion of 0.6 mg/h of bupivacaine
Number of subjects: 42
Study 9089857 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with a continuous background infusion via microspinal catheters
Number of subjects: 42
Study 9089857 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of bupivacaine
Number of subjects: 42
Study 1443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.45 MAC
Number of subjects: 17
Study 1443742 — intervention group
Group type: COMPARATOR
Intervention: N2O at 0.6 MAC
Number of subjects: 17
Study 1443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ED50)
Number of subjects: 17
Study 1443742 — intervention group
Group type: COMPARATOR
Intervention: N2O (ED50)
Number of subjects: 17
Study 1443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and N2O
Number of subjects: 17
Study 1443742 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane vs N2O
Number of subjects: 17
Study 3510540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with sympathomimetics and methylxanthines
Number of subjects: 157
Study 3510540 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 157
Study 3510540 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol alone
Number of subjects: 157
Study 3510540 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol alone (in patients with severe airflow obstruction)
Number of subjects: 157
Study 3510540 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone (in patients with severe airflow obstruction)
Number of subjects: 157
Study 31929472 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin taken before bedtime
Number of subjects: 147
Study 31929472 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin taken after breakfast
Number of subjects: 147
Study 31929472 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin taken after dinner
Number of subjects: 147
Study 29668699 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus (Göteborgs Rapé)
Number of subjects: 29
Study 29668699 — intervention group
Group type: COMPARATOR
Intervention: Tobacco free snus (Onico)
Number of subjects: 29
Study 26103979 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive spacing of TNF-blocker injections (S-arm)
Number of subjects: 137
Study 26103979 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of TNF-blocker injections (M-arm)
Number of subjects: 137
Study 25793955 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ingestion of a mixture of probiotics in addition to brushing teeth and using fluoridated toothpaste.
Number of subjects: 40
Study 25793955 — intervention group
Group type: COMPARATOR
Intervention: Brushing teeth and using fluoridated toothpaste without probiotics.
Number of subjects: 40
Study 23232966 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of cefazolin intramuscularly (reference group)
Number of subjects: 1046
Study 23232966 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of isotonic sodium chloride solution (study group)
Number of subjects: 1046
Study 20646688 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 160
Study 20646688 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 160
Study 20646688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 18236391 — intervention group
Group type: COMPARATOR
Intervention: FK (trough, 6‐10 ng/mL)
Number of subjects: 60
Study 18236391 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA (C2, 600‐1200 ng/mL)
Number of subjects: 60
Study 18236391 — intervention group
Group type: EXPERIMENTAL
Intervention: C2
Number of subjects: 60
Study 18236391 — intervention group
Group type: COMPARATOR
Intervention: FK
Number of subjects: 60
Study 16774104 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate ointment
Number of subjects: 0
Study 16774104 — intervention group
Group type: COMPARATOR
Intervention: Other clobetasol propionate preparations (solution, foam, cream, lotion, shampoo, emollient)
Number of subjects: 0
Study 14660202 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness training added to treatment
Number of subjects: 29
Study 14660202 — intervention group
Group type: COMPARATOR
Intervention: Multifaceted treatment (without fitness training)
Number of subjects: 29
Study 10741688 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (0.25 IU x kg per week)
Number of subjects: 20
Study 10741688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first 6 months) then switched to GH therapy
Number of subjects: 20
Study 10741688 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 20
Study 8694313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron, 0.15 mg/kg
Number of subjects: 60
Study 8694313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1552202 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated trivalent cold-recombinant influenza vaccine (10^5 TCID50 of each strain)
Number of subjects: 32
Study 1552202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1552202 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated trivalent cold-recombinant influenza vaccine
Number of subjects: 32
Study 31542838 — intervention group
Group type: EXPERIMENTAL
Intervention: Q1.6 smartphone application
Number of subjects: 0
Study 31542838 — intervention group
Group type: COMPARATOR
Intervention: Classical measurements
Number of subjects: 0
Study 31430268 — intervention group
Group type: EXPERIMENTAL
Intervention: RPh201 (20 mg) administered subcutaneously twice weekly
Number of subjects: 22
Study 31430268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cottonseed oil vehicle) administered subcutaneously twice weekly
Number of subjects: 22
Study 28419650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin 5 mg/mirabegron 25 mg, increasing to 50 mg after week 4)
Number of subjects: 0
Study 28419650 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 0
Study 28419650 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 0
Study 28419650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 25304838 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylscopolamine (20 mg intravenously immediately before the end of the operation)
Number of subjects: 99
Study 25304838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication for prevention of CRBD)
Number of subjects: 99
Study 23720276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous BM-MNC
Number of subjects: 54
Study 23720276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intramyocardial and intracoronary injection of autologous BM-MNC
Number of subjects: 54
Study 23720276 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art medical management (Control)
Number of subjects: 54
Study 21851883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient rate control
Number of subjects: 517
Study 21851883 — intervention group
Group type: COMPARATOR
Intervention: Strict rate control
Number of subjects: 517
Study 21851883 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex (independent variable)
Number of subjects: 517
Study 20381972 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute brief intervention
Number of subjects: 114
Study 20381972 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-minute brief intervention
Number of subjects: 114
Study 20381972 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 114
Study 17682094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline (600 mg every 12 h)
Number of subjects: 100
Study 17682094 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (i.v. vancomycin 1 g every 12 h with or without adjunctive i.v. aztreonam 1 g every 8 h)
Number of subjects: 100
Study 17682094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 100
Study 17682094 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 100
Study 15026871 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 61
Study 12097849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 106
Study 12097849 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 106
Study 9421387 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg once daily)
Number of subjects: 29
Study 7652582 — intervention group
Group type: EXPERIMENTAL
Intervention: INF-alpha therapy
Number of subjects: 0
Study 7652582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of INF-alpha therapy with other chemotherapeutic agents and/or biologicals
Number of subjects: 0
Study 2673315 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (chronic oral treatment for 8 weeks)
Number of subjects: 23
Study 2673315 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (acute intravenous administration)
Number of subjects: 23
Study 2673315 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (chronic oral treatment)
Number of subjects: 23
Study 2673315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 790413 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluphenazine (5-20 mg)
Number of subjects: 0
Study 790413 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot fluphenazine (25 mg/q 3 weeks)
Number of subjects: 0
Study 790413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and depot fluphenazine
Number of subjects: 0
Study 790413 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine (as needed)
Number of subjects: 0
Study 790413 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and depot fluphenazine
Number of subjects: 0
Study 790413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage equivalence
Number of subjects: 0
Study 31763307 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider endoscopic sinus surgery (ESS)
Number of subjects: 60
Study 31763307 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic sinus surgery (ESS)
Number of subjects: 60
Study 28976825 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 104
Study 28976825 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze dressings
Number of subjects: 104
Study 26235006 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales
Number of subjects: 160
Study 26235006 — intervention group
Group type: EXPERIMENTAL
Intervention: Problematic family functioning
Number of subjects: 160
Study 26235006 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger household size
Number of subjects: 160
Study 26235006 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse neurological event(s) during therapy
Number of subjects: 160
Study 24373344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) - 3 monthly injections of 1.25 mg
Number of subjects: 86
Study 24373344 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone (IVT) - 2 injections of 2 mg 2 months apart
Number of subjects: 86
Study 23403997 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of plaque
Number of subjects: 0
Study 23403997 — intervention group
Group type: COMPARATOR
Intervention: No plaque (Control group)
Number of subjects: 0
Study 18786981 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin (GC)
Number of subjects: 241
Study 18786981 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Etoposide (PE)
Number of subjects: 241
Study 17965485 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel or ticlopidine (Group I, n=28)
Number of subjects: 59
Study 17965485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel or ticlopidine plus cilostazol (Group II, n=31)
Number of subjects: 59
Study 15039501 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure (disclosure writing)
Number of subjects: 48
Study 15039501 — intervention group
Group type: COMPARATOR
Intervention: Control writing (writing about positive events)
Number of subjects: 48
Study 11193233 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) oral suspension of 800 mg/d for 12 weeks
Number of subjects: 69
Study 11193233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9777138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog and aspirin before streptokinase
Number of subjects: 17000
Study 9777138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin with streptokinase
Number of subjects: 17000
Study 9777138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog with streptokinase
Number of subjects: 17000
Study 9777138 — intervention group
Group type: COMPARATOR
Intervention: Heparin with streptokinase
Number of subjects: 17000
Study 8172139 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 5
Study 8172139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment or placebo)
Number of subjects: 5
Study 2898499 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub
Number of subjects: 2015
Study 2898499 — intervention group
Group type: COMPARATOR
Intervention: Plain soap (Control)
Number of subjects: 2015
Study 2898499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2015
Study 30522806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 0.5–0.6 × 10^8 allogenic placenta-derived MSCs
Number of subjects: 20
Study 30522806 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 20
Study 28152327 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-implemented Project ImPACT (2 hours per week)
Number of subjects: 9
Study 26353784 — intervention group
Group type: EXPERIMENTAL
Intervention: Truce program (7-week acceptance and commitment therapy)
Number of subjects: 65
Study 26353784 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 65
Study 23410527 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy inhalation
Number of subjects: 13
Study 23410527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 13
Study 21646292 — intervention group
Group type: EXPERIMENTAL
Intervention: Campaign advertisements
Number of subjects: 0
Study 21646292 — intervention group
Group type: COMPARATOR
Intervention: Consumer adverts (control)
Number of subjects: 0
Study 19142978 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelox (combination of l-arginine aspartate and Pycnogenol)
Number of subjects: 50
Study 19142978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17519075 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐12/23 mAb (0.27, 0.675, 1.35, and 2.7 mg/kg)
Number of subjects: 21
Study 17519075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17519075 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐12/23 mAb
Number of subjects: 21
Study 16145426 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 514
Study 16145426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 12359791 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (applied for 60 minutes)
Number of subjects: 30
Study 12359791 — intervention group
Group type: EXPERIMENTAL
Intervention: ELA-Max (applied for 30 minutes)
Number of subjects: 30
Study 10606880 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH), 250 U/kg twice daily
Number of subjects: 12
Study 10606880 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH), 300 U/kg once daily
Number of subjects: 12
Study 10606880 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin, 200 U/kg once daily
Number of subjects: 12
Study 10606880 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin, 1.5 mg/kg once daily
Number of subjects: 12
Study 7750288 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamin C (gram quantities)
Number of subjects: 0
Study 7750288 — intervention group
Group type: COMPARATOR
Intervention: Combination oral contraceptive alone
Number of subjects: 0
Study 2292897 — intervention group
Group type: EXPERIMENTAL
Intervention: Teolin 300 tablets (TT)
Number of subjects: 7
Study 2292897 — intervention group
Group type: COMPARATOR
Intervention: Teotard 350 capsules (TC)
Number of subjects: 7
Study 7016451 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg tolmetin sodium daily
Number of subjects: 70
Study 7016451 — intervention group
Group type: COMPARATOR
Intervention: 500 mg naproxen daily
Number of subjects: 70
Study 31180146 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic feedback device fitted to existing syringes
Number of subjects: 14
Study 27896797 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up to Quit (SUTQ) intervention
Number of subjects: 101
Study 27896797 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation counseling (control)
Number of subjects: 101
Study 25517106 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sucrose drink containing 6 g of l-citrulline
Number of subjects: 22
Study 25517106 — intervention group
Group type: EXPERIMENTAL
Intervention: 710 mL of watermelon juice (1.0 g citrulline)
Number of subjects: 22
Study 25517106 — intervention group
Group type: COMPARATOR
Intervention: 7.5% sucrose placebo drink
Number of subjects: 22
Study 24315273 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar scent (vanillin) exposure during arterial puncture after familiarization with the scent for an average of 8.65 hours.
Number of subjects: 135
Study 24315273 — intervention group
Group type: COMPARATOR
Intervention: Non-familiarized scent exposure during arterial puncture.
Number of subjects: 135
Study 24315273 — intervention group
Group type: COMPARATOR
Intervention: No scent exposure during arterial puncture.
Number of subjects: 135
Study 24315273 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar scent (vanillin) exposure during arterial puncture.
Number of subjects: 135
Study 21679291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (single pre-prandial dose)
Number of subjects: 106
Study 21679291 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (basal-only control)
Number of subjects: 106
Study 19906123 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation writing assignment
Number of subjects: 405
Study 19906123 — intervention group
Group type: COMPARATOR
Intervention: Control writing assignment
Number of subjects: 405
Study 16904450 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic local anesthesia (Group 1)
Number of subjects: 100
Study 16904450 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (Group 2)
Number of subjects: 100
Study 15012046 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during dialysis (cycling ergometer sessions, twice weekly for 12 sessions)
Number of subjects: 17
Study 15012046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 17
Study 11708421 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 74
Study 11708421 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PR)
Number of subjects: 74
Study 11708421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study 9076247 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired tone condition (MMF.P)
Number of subjects: 0
Study 9076247 — intervention group
Group type: COMPARATOR
Intervention: Single tone condition (MMF.S)
Number of subjects: 0
Study 9076247 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired tone condition
Number of subjects: 0
Study 9076247 — intervention group
Group type: COMPARATOR
Intervention: Single tone condition
Number of subjects: 0
Study 9076247 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired stimuli
Number of subjects: 0
Study 8426028 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient Geriatric Consultation Team (multidimensional geriatric assessment)
Number of subjects: 120
Study 8426028 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 120
Study 3149155 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine + Fentanyl
Number of subjects: 90
Study 3149155 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine + Alfentanil
Number of subjects: 90
Study 3149155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 90
Study 3149155 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 90
Study 3149155 — intervention group
Group type: COMPARATOR
Intervention: Control (no atropine, no analgetic)
Number of subjects: 90
Study 3149155 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 90
Study 29111077 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5 mA, 30 min, 20 sessions over 4 weeks)
Number of subjects: 130
Study 29111077 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (0.034 mA and two 60‐second current ramps up to 1 and 0.5 mA, 20 sessions over 4 weeks)
Number of subjects: 130
Study 27225596 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular entrée
Number of subjects: 183
Study 27225596 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein entrée
Number of subjects: 183
Study 27225596 — intervention group
Group type: COMPARATOR
Intervention: Control (self-selected foods)
Number of subjects: 183